Amgen (AMGN)
(Delayed Data from NSDQ)
$333.83 USD
+2.82 (0.85%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $332.11 -1.72 (-0.52%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$333.83 USD
+2.82 (0.85%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $332.11 -1.72 (-0.52%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Amgen to Buy Horizon Therapeutics: ETFs to Bet On
by Sweta Killa
Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.
5 Dow Stocks That Helped the Index Minimize Loss in 2022
by Vaishali Doshi
Here we have shortlisted five stocks - CVX, MRK, AMGN, TRV and IBM- that have fared better than the Dow Jones Index this year and have more upside potential for investment consideration.
Company News for Dec 13, 2022
by Zacks Equity Research
Companies in The News Are: COUP,HZNP,AMGN,RIVN,BA
Mirati (MRTX) Up on FDA Nod to Adagrasib for KRAS Mutated NSCLC
by Zacks Equity Research
The accelerated approval of Mirati Therapeutics' (MRTX) Krazati is based on ORR and DOR data from the phase II registration-enabling cohort of the KRYSTAL-1 study.
Amgen (AMGN) to Buy Horizon Therapeutics For $27.8 Billion
by Zacks Equity Research
Amgen (AMGN) wins the race to buy Horizon Therapeutics and makes an acquisition offer of $27.8 billion.
Wall Street Awaits Key Fed FOMC Decision
by Zacks Equity Research
Wall Street Awaits Key Fed FOMC Decision
Busy Week Highlighted by Next Fed Rate Move
by Mark Vickery
Consensus is currently for a 50 basis point (bps) hike mid-week, which will bring the Fed funds rate over +4% for the first time in 15 years.
Take the Zacks Approach to Beat the Market: NVIDIA, Boeing, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Mirati (MRTX) Down After 1st-Line Lung Cancer Data on Adagrasib
by Zacks Equity Research
Mirati Therapeutics' (MRTX) preliminary data from the first-line NSCLC study showed that adagrasib plus Merck's Keytruda achieved an objective response rate of 49%.
Horizon (HZNP) Up on Initial Talks of Buyout by Pharma Giants
by Zacks Equity Research
Horizon (HZNP) holds preliminary discussions with Amgen, Sanofi and Janssen, a subsidiary of J&J, seeking an offer for its acquisition by any one of the pharma giants. Shares rise.
Beat the Market the Zacks Way: Tenaris, Lululemon, AutoZone in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Mirati's (MRTX) Stock Rallies 11% on Buyout Speculations
by Zacks Equity Research
Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated KRASG12C-mutated NSCLC is under review with the FDA with a decision expected by Dec 14.
Buy this Medical Sector Pioneer Stock
by Shaun Pruitt
Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Take the Zacks Approach to Beat the Market: Axon, Rollins, Starbucks in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron
by Zacks Equity Research
CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.
Key Factors Driving Amgen's (AMGN) Outperformance This Year
by Zacks Equity Research
Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
The Zacks Analyst Blog Highlights Novo Nordisk, Amgen, Automatic Data Processing, Equinor and Illinois Tool Works
by Zacks Equity Research
Novo Nordisk, Amgen, Automatic Data Processing, Equinor and Illinois Tool Works are included in this Analyst Blog.
Top Research Reports for Novo Nordisk, Amgen & ADP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Amgen Inc. (AMGN) and Automatic Data Processing, Inc. (ADP).
Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Beat the Market Like Zacks: JPMorgan, Berkshire Hathaway, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update
by Zacks Equity Research
Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.